Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation reports developments in synthetic biology built around its silicon-based DNA synthesis platform. Company updates cover synthetic DNA tools and services for diagnostics, therapeutics, industrial, agriculture and research markets, including oligos, genes, proteins, libraries, characterization data, antibody discovery solutions and NGS workflow tools.
Recurring announcements include fiscal results, business updates, product launches such as expanded clonal gene capabilities and library preparation kits, antibody discovery licensing, investor presentations and Nasdaq inducement equity awards for new employees.
Twist Bioscience (Nasdaq: TWST) and MOLCURE Inc. have announced a collaboration that resulted in the generation of potent antibodies for an undisclosed oncology target, enhancing Twist's internal pipeline. This partnership leverages Twist's antibody discovery and optimization technology alongside MOLCURE's AI capabilities. Both companies expressed optimism about the potential advancements in drug discovery from this collaboration. Twist continues to innovate in synthetic biology, aiming for long-term growth across various sectors, including healthcare and agriculture.
Twist Bioscience Corporation (Nasdaq: TWST) has commenced shipping synthetic RNA reference controls for the SARS-CoV-2 Delta variants B.1.617.2 and B.1.617.3, which are swiftly spreading globally. CEO Emily M. Leproust emphasized the ongoing pandemic challenges and the company’s commitment to offering essential synthetic DNA and RNA products aimed at combating COVID-19. Twist's offerings include NGS assays and a broad range of infectious disease panels. The synthetic controls are sequence-verified and cover the entire viral genome, addressing the evolution of SARS-CoV-2.
Twist Bioscience Corporation (NASDAQ: TWST) will announce its fiscal 2021 third-quarter financial results on August 6, 2021, before market open. A conference call is scheduled for 8:00 a.m. ET to discuss the results and provide a business update. Twist, known for its innovative synthetic DNA technology, is focused on various sectors including healthcare and agriculture. Investors can access the financial results via the Investor Relations section of the company's website.
Twist Bioscience Corporation (Nasdaq: TWST) has announced the acquisition of iGenomX for $35 million, which includes $500,000 in cash and $29.5 million in stock, plus a $5 million contingent payment. This strategic acquisition aims to enhance Twist's multiplex sequencing capabilities and facilitate customer transitions from SNP microarrays to next-generation sequencing (NGS). Expected revenue from iGenomX is projected at $4-6 million for fiscal 2023, with minimal impact on the company’s expenses in fiscal 2021 and 2022.
Dovetail Genomics, a leader in genomic solutions, has launched its new capture Hi-C technology, which includes two targeted enrichment panels for human and mouse samples. These products enable analysis of chromatin topology surrounding 80,000 gene promoters, significantly reducing the sequencing burden by over 90%. The collaboration with Twist Bioscience enhances this offering with its proprietary enrichment technology, promising advancements in research addressing gene expression. CEO statements highlight the potential for new biomarkers and improved understanding of disease mechanisms.
Twist Bioscience Corporation (Nasdaq: TWST) has partnered with Regeneron Genetics Center to launch a custom next-generation sequencing assay called the Twist Diversity SNP Panel. This assay aims to improve understanding of genetic variations across global populations. It includes approximately 1.4 million representative SNPs, addressing the underrepresentation of diverse populations in genomic studies. By enabling a shift from traditional microarray methods, the panel seeks to enhance drug discovery and development for a wider range of populations.
Twist Bioscience Corporation (Nasdaq: TWST) announced CEO Emily Leproust's participation in a fireside chat at the BIO Digital conference, scheduled for June 17, 2021. The session will explore the role of synthetic DNA in applications such as diagnostic tools and therapeutic antibody development. Additionally, Chief Scientific Officer Aaron Sato will present on Twist Biopharma’s antibody discovery platform. Twist Bioscience is recognized for its innovative DNA synthesis technology, which is utilized across various industries including healthcare and agriculture.
The DNA Data Storage Alliance, created by Twist Bioscience (TWST), Illumina (ILMN), and Western Digital (WDC), has published a white paper titled “Preserving our Digital Legacy: An Introduction to DNA Data Storage.” This document discusses DNA storage's potential to address the exponential growth of digital data, highlighting that humans generated over 400 ZB of data in 2020. The paper outlines DNA's unprecedented storage density, stability, and sustainability compared to existing technologies. The Alliance aims to develop standards for interoperability in DNA storage solutions as the technology evolves.
Twist Bioscience (Nasdaq: TWST) has commenced shipping synthetic RNA reference controls for the SARS-CoV-2 Kappa variant (B.1.617.1). The company is also developing controls for the Delta (B.1.617.2) and B.1.617.3 variants. This initiative comes as India faces a significant COVID-19 outbreak and a high number of unvaccinated individuals. CEO Emily M. Leproust highlighted the company's commitment to provide essential tools to combat the virus globally, including controls for detecting new strains. Twist aims to support health and sustainability through its sophisticated DNA synthesis platform.
Twist Bioscience Corporation (Nasdaq: TWST) has launched the Twist Library Preparation Enzymatic Fragmentation Kit 2.0, an all-in-one solution designed to enhance accuracy and efficiency in library construction for next-generation sequencing (NGS). This kit is particularly suitable for challenging applications, including liquid biopsy and somatic variant testing, and excels with samples of limited or degraded DNA, such as banked oncology samples. The launch emphasizes the importance of robust sample preparation technologies for generating high-quality sequencing data.